类器官模型在肿瘤精准诊疗中的应用

王海霞; 张聪; 邹冬玲

doi:10.12354/j.issn.1000-8179.2023.20221125

类器官模型在肿瘤精准诊疗中的应用

doi: 10.12354/j.issn.1000-8179.2023.20221125

王海霞^1,,
张聪²,
邹冬玲^1, ,

1.
重庆大学附属肿瘤医院妇科肿瘤中心（重庆市400030）
2.
重庆大学医学院生物与医药专业

基金项目: 本文课题受国家自然科学基金面上项目（编号：82073129）、重庆市卫生适宜技术推广项目（编号：2021jstg001）、北京科创基金项目（编号：KC2021-JX-0186-129）、重庆市科技局项目（编号：2023ZDXM029、cstc2020jxjl130019）和重庆市沙坪坝区科技局项目（编号：Jcd2022102）资助

详细信息

作者简介:
王海霞：专业方向为卵巢癌发生发展及复发耐药机制的研究

通讯作者:
邹冬玲　13570049@qq.com

计量
- 文章访问数: 31
- HTML全文浏览量: 3
- PDF下载量: 20
- 被引次数: 0
出版历程
- 收稿日期: 2022-08-01
- 录用日期: 2022-11-24
- 修回日期: 2022-10-06

The application of organoid models in cancer precision medicine

1.
Departments of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing 400030, China
2.
Biological and Pharmaceutical Engineering, School of Medicine Chongqing University, Chongqing 400030, China

Funds: This work was supported by the National Natural Science Foundation of China (No. 82073129), Chongqing Health Appropriate Technology Promotion Project (No. 2021jstg001), Beijing Science & Technology Innovation Fund (No. KC2021-JX-0186-129), Chongqing Science and Technology Bureau (No. 2023ZDXM029, No. cstc2020jxjl130019), and Chongqing Shapingba District Bureau of Science and Technology (No. Jcd2022102)

More Information

Corresponding author: Dongling Zou; E-mail:13570049@qq.com

摘要

摘要: 过去10年中，三维类器官技术得到了快速发展，目前已经可以从正常组织和恶性肿瘤组织中高效地建立类器官。患者来源的肿瘤类器官（patient-derived tumor- organoids，PDOs）可以很好地保留亲本肿瘤的生理病理学及遗传学特征，最大限度地保持肿瘤异质性。PDOs已被用于阐明关键的科学问题，包括感染病原体或遗传/表观遗传学改变与肿瘤发生之间的关系、耐药机制、预测患者对选定治疗方案的反应。随着类器官与肿瘤微环境的细胞成分共培养系统的建立，该技术现在也被应用于快速发展的免疫肿瘤学领域。本文综述了类器官技术在肿瘤精准医学领域的研究现状、应用及面临的挑战。
- 类器官 /
- 肿瘤 /
- 精准诊疗
Abstract: Three-dimensional organoid technology has remarkably improved with enhanced efficiency in developing organoids from both normal and malignant tissues of patients over the past decade. Patient-derived tumor organoids (PDOs) retain the physiopathological and genetic characteristics of the tumor while providing a high level of patient-specific tumor heterogeneity. PDOs shed light on crucial scientific topics, including the relationship between infectious pathogens or genetic/epigenetic alterations and tumorigenesis, the mechanism of drug resistance, and the prediction of the patient response to specific treatments. With the establishment of tumor organoids and cellular components of the tumor microenvironment, such as immune cell co-culture systems, this technique is now utilized in the rapidly growing field of immuno-oncology. This review discusses the current achievements, applications, and challenges of organoid technology in cancer precision medicine.
- organoids /
- cancer /
- precision medicine

HTML全文

参考文献(32)

[1]	Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche[J]. Nature, 2009, 459(7244):262-265. doi: 10.1038/nature07935
[2]	Idris M, Alves MM, Hofstra RMW, et al. Intestinal multicellular organoids to study colorectal cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2):188586. doi: 10.1016/j.bbcan.2021.188586
[3]	Kopper O, de Witte CJ, Lõhmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity[J]. Nat Med, 2019, 25(5):838-849. doi: 10.1038/s41591-019-0422-6
[4]	Maenhoudt N, Defraye C, Boretto M, et al. developing organoids from ovarian cancer as experimental and preclinical models[J]. Stem Cell Reports, 2020, 14(4):717-729. doi: 10.1016/j.stemcr.2020.03.004
[5]	Lo Y H, Kolahi K S, Du Y, et al. A CRISPR/Cas9-Engineered ARID1A-deficient human gastric cancer organoid model reveals essential and nonessential modes of oncogenic transformation[J]. Cancer Discov, 2021, 11(6):1562-1581. doi: 10.1158/2159-8290.CD-20-1109
[6]	Huang W, Navarro-Serer B, Jeong YJ, et al. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome[J]. Cancer Res, 2020, 80(13):2804-2817. doi: 10.1158/0008-5472.CAN-19-1523
[7]	Rosenbluth JM, Schackmann RCJ, Gray GK, et al. Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages[J]. Nat Commun, 2020, 11(1):1711. doi: 10.1038/s41467-020-15548-7
[8]	Sampaziotis F, Muraro D, Tysoe OC, et al. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver[J]. Science, 2021, 371(6531):839-846. doi: 10.1126/science.aaz6964
[9]	Silvestri VL, Henriet E, Linville RM, et al. A tissue-engineered 3D microvessel model reveals the dynamics of mosaic vessel formation in breast cancer[J]. Cancer Res, 2020, 80(19):4288-4301. doi: 10.1158/0008-5472.CAN-19-1564
[10]	Bartfeld S, Bayram T, van de Wetering M, et al. In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection[J]. Gastroenterology, 2015, 148(1):126-136.e6. doi: 10.1053/j.gastro.2014.09.042
[11]	McCracken KW, Catá EM, Crawford CM, et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids[J]. Nature, 2014, 516(7531):400-404. doi: 10.1038/nature13863
[12]	Scanu T, Spaapen RM, Bakker JM, et al. Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma[J]. Cell Host Microbe, 2015, 17(6):763-774. doi: 10.1016/j.chom.2015.05.002
[13]	De Crignis E, Hossain T, Romal S, et al. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma[J]. Elife, 2021, 10:e60747. doi: 10.7554/eLife.60747
[14]	Lõhmussaar K, Oka R, Espejo Valle-Inclan J, et al. Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer[J]. Cell stem cell, 2021, 28(8):1380-1396. doi: 10.1016/j.stem.2021.03.012
[15]	Matano M, Date S, Shimokawa M, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids[J]. Nat Med, 2015, 21(3):256-262. doi: 10.1038/nm.3802
[16]	Drost J, van Jaarsveld RH, Ponsioen B, et al. Sequential cancer mutations in cultured human intestinal stem cells[J]. Nature, 2015, 521(7550):43-47. doi: 10.1038/nature14415
[17]	Dekkers JF, Whittle JR, Vaillant F, et al. Modeling breast cancer using CRISPR-Cas9-mediated engineering of human breast organoids[J]. J Natl Cancer Inst, 2020, 112(5):540-544.
[18]	Chen P, Zhang X, Ding R, et al. Patient-derived organoids can guide personalized-therapies for patients with advanced breast cancer[J]. Adv Sci (Weinh), 2021, 8(22):e2101176.
[19]	Yao Y, Xu X, Yang L, Zhu J, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer[J]. Cell stem cell, 2020, 26(1):17-26. doi: 10.1016/j.stem.2019.10.010
[20]	Driehuis E, van Hoeck A, Moore K, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening[J]. Proc Natl Acad Sci U S A, 2019, 116(52):26580-26590.
[21]	Wensink GE, Elias SG, Mullenders J, et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients[J]. NPJ Precis Oncol, 2021, 5(1):30. doi: 10.1038/s41698-021-00168-1
[22]	Beshiri ML, Tice CM, Tran C, et al. A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening[J]. Clin Cancer Res, 2018, 24(17):4332-4345. doi: 10.1158/1078-0432.CCR-18-0409
[23]	Pamarthy S, Sabaawy HE. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine[J]. Mol Cancer, 2021, 20(1):125. doi: 10.1186/s12943-021-01426-3
[24]	Welti J, Sharp A, Yuan W, et al. Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC)[J]. Clin Cancer Res, 2018, 24(13):3149-3162. doi: 10.1158/1078-0432.CCR-17-3571
[25]	赵冰,宋伟,王海霞.肿瘤类器官诊治平台的质量控制标准中国专家共识(2022年版)[J].中国癌症杂志,2022,32(7):657-68.
[26]	Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment[J]. Cell, 2018, 175(7):1972-1988. doi: 10.1016/j.cell.2018.11.021
[27]	Dijkstra KK, Cattaneo CM, Weeber F, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids[J]. Cell, 2018, 174(6):1586-1598. doi: 10.1016/j.cell.2018.07.009
[28]	Cattaneo CM, Dijkstra KK, Fanchi LF, et al. Tumor organoid-T-cell coculture systems[J]. Nat Protoc, 2020, 15(1):15-39. doi: 10.1038/s41596-019-0232-9
[29]	Meng Q, Xie S, Gray GK, et al. Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids[J]. J Immunother Cancer, 2021,9(11):e003213.
[30]	Schnalzger TE, de Groot MH, Zhang C, et al. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids[J]. EMBO J, 2019, 38(12):e100928
[31]	van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients[J]. Cell, 2015, 161(4):933-945.
[32]	Perrone F, Zilbauer M. Biobanking of human gut organoids for translational research[J]. Exp Mol Med, 2021, 53(10):1451-1458.